J. Harding

Patients (pts) with advanced hepatocellular carcinoma (HCC) with long-term response to immune checkpoint inhibitor (ICI) therapy

BackgroundLong-term responders to ICI occur in advanced HCC pts; though little is known about ultimate outcomes and treatment trajectory. A clinical knowledge gap exists for long-term dis...

R. Do ;

S. Folorunso ;

I. El Dika ;

A. Yaqubie ;

E. O'Reilly ;

J. Harding ;

T. Kim ;

D. Cowzer ;

F. Keane ;

D. Khalil ;

J. Shia ;

06/25/2023

James Harding, MD, Memorial Sloan Kettering Cancer Center

Videos

Novel Dual IDH-Inhibitor Plus Chemotherapy Showed Promising Efficacy, Safety for Patients With Advanced IDH-Mutant Cholangiocarcinoma

07/12/2023

J. Harding ;

According to a study presented at the 2023 World Congress on Gastrointestinal Cancers, the IDH1/2-inhibitor LY3410738 showed promising efficacy and safety in combination with chemotherapy for patients with locally advanced or metastatic...

According to a study presented...

07/12/2023

Oncology